| To: TokyoMex who wrote () | 2/14/2000 9:58:00 AM | | From: etcobbe | | | |
RGEN - FDA approval today - One of a kind drug.
Monday February 14, 6:45 am Eastern Time
Company Press Release
SOURCE: Repligen Corporation
Repligen Issued Broad U.S. Patent For Use of Secretin In The Treatment of Autism
NEEDHAM, Mass., Feb. 14 /PRNewswire/ -- Repligen Corporation (Nasdaq: RGEN - news) today announced it was awarded a U.S. patent for the use of secretin in the treatment of autism spectrum disorder and its symptoms. U.S. patent No. 6,020,310 is entitled ``Method for assisting in differential diagnosis and treatment of autistic syndromes.'
The patent, which will remain in force until 2018, covers intravenous administration of secretin for the treatment of autism spectrum disorder and its symptoms, as well as methods where secretin is co-administered with a permeation-enhancing agent.
In March 1999, Repligen acquired exclusive rights to a series of patent applications for the use of secretin, a naturally-occurring hormone currently approved to diagnose certain gastrointestinal conditions, as a potential autism therapy. Some autistic children who have received the hormone therapeutically have made improvements in social behavior, communication, gastrointestinal function and sleep. Repligen is developing a human synthetic form of secretin for evaluation in clinical trials in pediatric autism.
``This patent allowance gives us a strong proprietary position with regard to secretin as a potential new treatment for autism, a pervasive and debilitating developmental disorder for which there are no FDA approved treatments currently available,' said Walter C. Herlihy, Ph.D., President and CEO of Repligen. ``We are currently prosecuting additional patent applications in the United States and Europe to further strengthen our position.'
The patent also discloses a previously unrecognized relationship between the response of the pancreas to secretin stimulation and autism. A recent study published in the Journal of Pediatrics (Horvath et al, Journal of Pediatrics 135 (5): 559-63) showed that 75% of autistic children with gastrointestinal symptoms had a significantly greater pancreatic response to secretin compared to children without the disorder, suggesting lack of normal secretin stimulation in this subset of autistic patients. Conducted at the University of Maryland Medical Center, the study was designed to understand the underlying biology of secretin in autism.
Autism is a neurological disorder that typically appears during the first three years of life and is characterized by defects in social interaction, communication and abnormal behavior. It is the third most common developmental disability in the United States today, affecting at least half-a-million people. There is no FDA-approved treatment for autism.
Repligen Corporation develops new drugs for autism, organ transplant and cancer. Repligen also manufactures and markets a set of patented products based on Protein A, which are used by the pharmaceutical industry to produce therapeutic antibodies. Its corporate headquarters are located at 117 Fourth Avenue, Needham MA, 02494. Additional information may be requested from www.repligen.com. |
| | Tokyo Joe's Cafe / Anything goes | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: TokyoMex who wrote () | 2/14/2000 3:46:00 PM | | From: StalkFunder | | | |
hey, put TCBG on your watch list... if they don't go bankrupt...
it could reclaim the terrible 2's real quick
this is old Daytraders.com player's play... nothing says co won't go BK tomorrow morning! |
| | Tokyo Joe's Cafe / Anything goes | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: TokyoMex who wrote () | 2/16/2000 2:26:00 PM | | From: beats_the_s_p500 | | | |
Analyst Report on Nova Pharmaceutical Inc. Claims Opportunity For Strategic Investors
LAKE ELSINORE, Calif., Feb. 16 /PRNewswire/ -- Nova Pharmaceutical Inc. (OTC Bulletin Board: NOVX) announced today the publication of an independent analysts report released by National Capital Securities (NCS) Research with a recommendation to Buy.
"Nova has completed its development stage and is positioned as a leader in the natural dietary and health supplement industry," says NCS. "The Company's flagship product, NxTrim is a patented, all-natural weight loss aid. According to a retail tracking report provided by the Information Resources Inc., NxTrim held the #1 ranking for diet aids in the California Drug market through 1999," NCS added.
Ralph Mann, President and CEO of Nova, said, "We believe that our company is positioned for rapid growth in the ever growing natural products industry." NCS says, "The Company is able to maintain low overhead, but still is capable of quickly responding to consumer demand."
The analyst report provides details about the nature of Nova's business, its conception, and its products and services. It also demonstrates the Company's financials and investment opinion. "We believe that Nova Pharmaceutical Inc presents a new opportunity for risk-oriented, strategic investors in this developing industry of nutritional supplements," says NCS. NCS adds, "Considering the Company's long term, steady growth outlook, we believe Nova Pharmaceutical Inc is an attractive investment and is targeting a stock price of $10 within the next 18 to 24 months."
About Nova Pharmaceutical Inc.
Nova Pharmaceutical Inc. is a publicly traded company on the OTC Bulletin Board (ticker symbol:NOVX). The company's patented weight loss product, NxTrim, achieved first year sales of $2,000,000, and is currently the number one selling diet aid in the California Drug class of trade according to data provided by Information Resources Inc.
Nova Pharmaceutical Inc is the sole manufacturer, distributor, and marketer of Gold's Gym Nutrition supplements. The company has twenty-three items under the Gold's Gym trademark.
Certain statements in this release are "forward looking" statements as such term is defined in the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
--------------------------------------------------------------------------------
SOURCE: Nova Pharmaceutical Inc.
CONTACT: Ralph Mann, CEO & President, or Jim Ayres, Vice President & Secretary, both of Nova Pharmaceutical Inc., 888-495-NOVA (6682), jim@novanx.com; or Joe Stapley of Travis Morgan Securities, 949-261-2906, for Nova Pharmaceutical Inc. |
| | Tokyo Joe's Cafe / Anything goes | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: TokyoMex who wrote () | 2/17/2000 10:43:00 AM | | From: beats_the_s_p500 | | | |
(PR Wires) PRW: Nova Pharmaceutical Inc. Signs Deal with Gold's Gym Int
PRW: Nova Pharmaceutical Inc. Signs Deal with Gold's Gym International for
Exclusive Nutrition Manufacturing
LAKE ELSINORE, Calif., Feb. 17 /PRNewswire/ -- Nova Pharmaceutical Inc. (OTC
Bulletin Board: NOVX) announced today that is has signed a three-year
renewable agreement with Gold's Gym International, Inc., the licensing
division of Gold's Gym Enterprises, Inc., for exclusive manufacturing and
marketing of Gold's Gym nutritional and sports supplement products.
Gold's Gym, founded in 1965, has become the most recognized name in the
fitness industry. Its historic Venice Beach gym has hosted such
professional athletes as Arnold Schwarzenegger, Lou Ferrigno and Mark
McGuire. There are more than 500 Gold's Gym locations worldwide, with a
total of more than 2 million members. Gold's Gym has supported its brand
name for years with signature accessories such as T-shirts, gym bags,
jackets and other items which display the Gold's Gym logo. Nova
Pharmaceutical launched 23 products under the Gold's Gym trademark, at the
Gold's Gym Expo held annually in Las Vegas. The product line ranges from
specialized sports nutrition supplements to general health products.
Product information and details are available at www.goldsgymnutrition.com.
In addition to the 500 Gold's Gym locations, Nova Pharmaceutical will
distribute the new product line through drug, food and mass merchandise
stores. Nova Pharmaceutical products currently are sold in more than 11,000
locations nationwide under the company's own brand.
About Nova Pharmaceutical Inc.
Nova Pharmaceutical Inc. is a publicly traded company on the OTC Bulletin
Board (ticker symbol: NOVX). The Company's patented weight loss product,
NxTrim, achieved first year sales of $2,000,000, and held the number one
ranking in diet aid sales in the California Drug market according to data
provided by Information Resources Inc.
Nova Pharmaceutical Inc. is the sole manufacturer, distributor, and marketer
of Gold's Gym Nutrition supplements. The Company has twenty-three products
under the Gold's Gym trademark.
More information about the products and services of Nova Pharmaceutical Inc.
are available at the Company's web site www.novanx.com. The Company also
hosts an informational web site for the Gold's Gym line of products at
www.goldsgymnutrition.com.
Certain statements in this release are "forward looking" statements as such
term is defined in the Private Securities Litigation Reform Act of 1995.
Because such statements are subject to risks and uncertainties, actual
results may differ materially from those expressed or implied by such
forward-looking statements.
/CONTACT: Ralph Mann, CEO & President, or Jim Ayres, Vice President,
jim@novanx.com, both of Nova Pharmaceutical Inc., 888-495-6682; or Joe
Stapley of Travis Morgan Securities, 949-261-2906/
08:31 EST
*** end of story *** |
| | Tokyo Joe's Cafe / Anything goes | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: TokyoMex who wrote () | 2/17/2000 12:05:00 PM | | From: blake roberts | | | |
I am looking for opinions on pink sheet EINI. Read and respond, thanks!:
From RB:
EINI
from what i have gathered, the company brought on as ceo industry heavyweight michael jay solomon, who has alot, and i emphasize alot, of clout in hollywood fundraising circles. i live in burbank and hear about this guy all the time. (these industry players love to talk; that is how i happen to come across the ticker). they are getting these entertainment-types in the stock the next couple of weeks to raise money for their debut on the otc market. from what the company has indicated, the price will be set at $5. they are turning a bb in to a $50 million company! in the meantime, retail investors are buying up the float, which explains the dramatic movement. i expect the institutional buyers to be brought on some time next week, after they meet with the hollywood glitteratti. don't know much about the acquisition news, but that would definately be a bonus; makes sense though - high profile otc debut and great news the same day. i am long 5,000 shares at .62 and i increased my position by 2500 today at 1.00 after i got word of what's goin on. man it's nice being in on the ground level!
(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)
- |
| | Tokyo Joe's Cafe / Anything goes | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (2) |
|
| |
